Prelude Therapeutics Inc — Director's Dealing 2021

Apr 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Prelude Therapeutics Inc (PRLD)
CIK: 0001678660
Period of Report: 2021-04-08

Reporting Person: Morosini Deborah (EVP, Chief of Clinical Affairs)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-08	Common Stock	M	100	$1.89	Acquired	544	Direct
2021-04-08	Common Stock	S	100	$40.00	Disposed	444	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-08	Employee Stock Option (right to buy)	$1.89	M	100	Disposed	2030-03-26	Common Stock (100)	Direct

Footnotes

F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: The stock option is fully vested.